Voyager Therapeutics Inc Stock
€3.34
Your prediction
Voyager Therapeutics Inc Stock
Pros and Cons of Voyager Therapeutics Inc in the next few years
Pros
Cons
Performance of Voyager Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Voyager Therapeutics Inc | 0.830% | -2.050% | -3.797% | 6.769% | -2.734% | -52.822% | -18.717% |
| Heron Therapeutics Inc. | -0.220% | 5.471% | -31.355% | -64.610% | -37.702% | -50.322% | -95.078% |
| Evolus Inc | -1.080% | 1.099% | 0.000% | -66.847% | -32.477% | -52.208% | -65.607% |
| Sangamo Therapeutics Inc. | 18.000% | -12.659% | -29.343% | -56.626% | -25.243% | -83.840% | -97.492% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Voyager (with US symbol VYGR) present a mixed bag of insights that highlight both challenges and resilience within the Biotechnology and Medical Research sector. A glance at the figures reveals a company that has been grappling with losses yet possesses assets and potential for recovery. The financial statements showcase an evolving narrative where investment in research and development is crucial for future growth, albeit at the expense of current profitability.
Starting with the positives, Voyager's balance sheet reflects a robust asset base, with total assets amounting to approximately $351.3 million as of December 31, 2023. This figure indicates that the company has a solid foundation on which to build future growth. Moreover, it maintains a healthy net working capital of about $255.2 million, suggesting that it can comfortably meet its short-term obligations, which reassures stakeholders regarding operational liquidity.
The cash flow statement for 2023 shows that Voyager generated $77.9 million from operating activities, ultimately leading to a positive free cash flow of about $74.7 million for the year. This cash flow capability could be attractive to investors, indicating that the company is still generating substantial cash, which is essential for funding research initiatives and sustaining operations despite the reported net losses.
News
Master Investor Ray Dalio's Strategy Shows Up in This ETF -- And It Could Help You Invest More Confidently
It's only when markets are choppy that investors find out what their real risk tolerance is. It's easy to fill out a questionnaire and say you'd be able to withstand a correction or bear market, but
Will This All-Weather ETF Live Up to Its Name?
With many exchange-traded funds, it's easy to predict how they'll perform. If you have an S&P 500 index ETF, for instance, all you have to do is look at the S&P's closing value to get a sense of how
Is This the One ETF to Rule Them All?
Exchange-traded funds are designed to be building blocks that are easy to put together. You can find stock-focused ETFs of all kinds, which you can mix and match to customize your own particular